NOTE
🌱 created from: treatment-of-myelofibrosis
bet_inhibitor
- Design: Phase I dose-escalation/expansion study, multicenter, open-label
- Number of patients: Not specified
- Patients characteristics: Patients with relapsed or refractory advanced myelofibrosis or other advanced hematologic malignancies
- Agent: BET inhibitor INCB057643 as monotherapy or in combination with JAK inhibitor ruxolitinib
- Treatment line: Relapsed or refractory patients, some in combination therapy
- Trial Acronym/NCTId Number: Not specified
- Comparison of efficacy:
| Parameter | Result |
|---|---|
| Symptom improvement | Effective |
| Treatment of anemia | Some success |
| Side effects | Minimal |
- Highlight of toxicity: Dosing at a level that did not produce side effects seen with other BET inhibitors
- One-line summary: INCB057643, a novel BET inhibitor, shows promise as a targeted therapy for advanced myelofibrosis and other hematologic malignancies, with minimal side effects and potential for improved outcomes.